COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT

Net proceeds are intended primarily to accelerate LightSolver's laser-based supercomputing research and development.

Rhea-AI Summary

CollPlant Biotechnologies (Nasdaq: CLGN) has signed definitive agreements for a private placement expected to raise approximately $3.7 million in gross proceeds.

The offering comprises 989,301 ordinary shares or equivalents and warrants to purchase up to 1,483,952 ordinary shares. The combined price is $3.74 per share and accompanying warrants, or $3.7399 per equivalent and accompanying warrants. Warrants are immediately exercisable upon issuance at $3.74 per share. Existing investors comprise most of the placement. CollPlant expects closing on or about October 14, 2026, subject to customary closing conditions, and intends to use net proceeds primarily to accelerate subsidiary LightSolver's laser-based computing research and development. Gross proceeds exclude placement-agent fees and related expenses.

2 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Private placement is expected to raise approximately $3.7 million in gross proceeds. 49% of market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.Net proceeds are intended primarily to accelerate LightSolver's research and development, including computing architecture and technology scalability.

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.989,301 ordinary shares or equivalents at $3.74 or $3.7399, respectively, with accompanying warrants, dilute holders.
• Minor point. Forward-looking: it has not happened yet and may not happen.Warrants for up to 1,483,952 ordinary shares, exercisable immediately upon issuance at $3.74, create potential additional dilution.
• Minor point. Forward-looking: it has not happened yet and may not happen.Placement-agent fees and related expenses will reduce the proceeds available to CollPlant.

News Explained

The signed placement is not yet closed: it covers 989,301 ordinary shares or equivalents, while its warrants are immediately exercisable and could add up to 1,483,952 shares; issuing these as shares increases the share count and reduces existing holders’ ownership percentages.

Key Figures

Placement amount: $3.7 million Ordinary shares: 989,301 shares Warrant coverage: Up to 1,483,952 ordinary shares +4 more

Placement amount

$3.7 million

Headline amount; gross proceeds before fees and expenses

Ordinary shares

989,301 shares

Aggregate securities to be issued, or ordinary share equivalents in lieu thereof

Warrant coverage

Up to 1,483,952 ordinary shares

Shares underlying the accompanying unregistered warrants

Purchase price

$3.74 per ordinary share and accompanying warrants

Combined purchase price

Warrant exercise price

$3.74 per share

Warrants exercisable immediately upon issuance

Warrant term

Five years

From the effective date of a registration statement covering warrant shares

Expected closing

October 14, 2026

Expected closing date, subject to customary conditions

Previous Private placement Reports

1 past event · Latest: Jun 30

Same Type 1 event

1. Jun 30

   Private placement

   24h Move

   -4.8%

   Announced a $2.6 million placement issuing ordinary shares or equivalents and warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

private placement, warrants, regulation d, registration statement

4 terms

private placement financial

"entered into definitive agreements for the issuance and sale"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

warrants financial

"unregistered warrants to purchase up to 1,483,952 ordinary shares"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

regulation d regulatory

"and/or Regulation D promulgated thereunder"

Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.

registration statement regulatory

"agreed to file a registration statement with the U.S. Securities and Exchange Commission"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Transaction Led Primarily by Existing Investors to Accelerate LightSolver's Laser-Based Supercomputing Development

REHOVOT, Israel, Oct. 9, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), an innovative technology company operating at the intersection of deep-tech photonic computing and biotechnology  today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 989,301 of the Company's ordinary shares (or ordinary share equivalents in lieu thereof) and unregistered warrants to purchase up to 1,483,952 ordinary shares in a private placement at a combined purchase price of $3.74 per ordinary share and accompanying warrants (or $3.7399 per ordinary share equivalent and accompanying warrants). The private placement, which is comprised primarily of the Company's existing investors, reflects confidence in CollPlant's expanded strategic vision and its execution capabilities in deep-tech photonic computing. The warrants will have an exercise price of $3.74 per share, will be exercisable immediately upon issuance and will expire five years after the effective date of a registration statement registering the shares issuable upon exercise of the warrants. The private placement is expected to close on or about October 14, 2026, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. and Rodman & Renshaw LLC are acting as the exclusive joint placement agents for the private placement.

The gross proceeds from the private placement, before deducting the placement agent's fees and other related expenses payable by the Company, are expected to be approximately $3.7 million. CollPlant intends to use the net proceeds  from this offering primarily to accelerate the research and development programs of its subsidiary, LightSolver, focusing on the advancement and scalability of its proprietary laser-based supercomputing architecture and Laser Processing Unit (LPU™) technology as well as general corporate purposes including working capital.

The offer and sale of the foregoing securities is being made in reliance on an exemption from the registration requirement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder, and applicable state securities laws, and the securities have not been and will not initially be registered under the Securities Act, or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to the terms of the securities purchase agreement entered into with the investors, the Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the resale of the ordinary shares and ordinary shares underlying the warrants sold in the private placement.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About CollPlant

CollPlant (Nasdaq: CLGN) is an innovative technology company operating at the intersection of deep-tech photonic computing and advanced biotechnology. Through its subsidiary LightSolver, CollPlant is advancing the development of proprietary all-optical laser based computing architectures designed to resolve the world's most demanding computational bottlenecks across artificial intelligence, aerospace, financial engineering, and high-performance computing. Concurrently, CollPlant remains a leader in regenerative medicine, pioneering plant-derived recombinant human collagen technologies for 3D bioprinting of tissues and organs and medical aesthetics.

For more information about CollPlant, visit http://www.collplant.com. 

Forward-Looking Statements 

This press release may include forward-looking statements. Forward-looking statements include, but are not limited to, statements relating to the completion of the private placement, the satisfaction of customary closing conditions related to the private placement and the intended use of proceeds from the private placement as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the risk that the anticipated benefits of the LightSolver transaction are not realized, or are not realized within the expected timeframe; risks associated with integrating LightSolver's business, operations and personnel; LightSolver's ability to achieve anticipated technological and commercial milestones; uncertainties regarding market acceptance and adoption of LightSolver's technology; the ability to develop and commercialize LightSolver's products and technology successfully; the ability to establish and expand strategic collaborations and commercial relationships; competition and technological developments; intellectual property risks; the availability of capital; CollPlant's ability to maintain compliance with Nasdaq listing requirements; general market, industry, economic and geopolitical conditions; and other risks and uncertainties described in CollPlant's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F and subsequent Reports on Form 6-K. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts 

CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@collplant.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/collplant-announces-a-3-7-million-private-placement-302903533.html

SOURCE CollPlant

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much will CollPlant's private placement raise, and what is the purchase price?

The placement is expected to raise approximately $3.7 million in gross proceeds before placement-agent fees and related expenses. The combined purchase price is $3.74 per ordinary share and accompanying warrants, or $3.7399 per ordinary share equivalent and accompanying warrants.

When is CollPlant's private placement expected to close?

CollPlant expects the private placement to close on or about October 14, 2026, subject to satisfaction of customary closing conditions.

When do the warrants in CollPlant's private placement expire?

The warrants expire five years after the effective date of a registration statement registering the shares issuable upon their exercise. That expiration period is tied to the registration statement's effective date, rather than the placement's closing date.